期刊文献+

多沙唑嗪对兔血脂和血管内膜增生的影响 被引量:2

Influence of Doxazosin on Vascular Stenosis after Balloon Injure in Rabbit Arteries
暂未订购
导出
摘要 目的:探讨多沙唑嗪对兔动脉球囊损伤后血管狭窄的影响及与血脂的关系。方法:23只新西兰兔随机分为3组,正常对照组用普通饲料喂养并不予任何处理。另两组用高脂饲料喂养并行腹主动脉球囊损伤术,多沙唑嗪组术后应用多沙唑嗪控释片4 m g/d灌胃,术后4周处死兔,观察各组血脂以及血管损伤处内膜、中膜厚度、新生内膜面积、管腔面积。结果:高脂喂养造成兔血脂明显增高。手术开始时多沙唑嗪组和球囊损伤组两组血脂水平无差异,手术4周后多沙唑嗪组总胆固醇较球囊损伤组降低,而高密度脂蛋白较球囊损伤组增高。术后多沙唑嗪组与球囊损伤组血管损伤处相比血管内膜增生减轻,新生内膜面积减少,管腔面积增加。结论:多沙唑嗪可以抑制高脂喂养加球囊损伤后兔腹主动脉血管的狭窄,可以降低血脂、抑制动脉粥样硬化进展。 Objective:To study the influence of doxazosin on vascular stenosis after balloon injured abdominal artery on the hyperlipidemic atherosclerotic model of rabbits. And to find its relationship with serum lipid. Methods : 23 New Zealand rabbits were randomlly divided into 3 groups. Normal contral group(n= 5) was fed with ordinary diet and without any administration. The other two groups were fed with 1% cholesterol diet,and their abdominal arteries were injured by dilated balloon. Meanwhile doxazosin group was fed with doxazosin controlled release tablet 4 mg/d. Blood lipid were measured and compared with each other at 4th weeks after operating. Intima thickness, Media thinkness, Neointima area,Lumen area were analyzed by Hias-1000 imagining analysis system. In 3 groups vascular stenosis were compared with each other after balloon injured. Results:The blood lipid in rabbit fed by high cholesterol diet were more higher. There were no differense in blood lipid at the begining of the test between doxazosin group and balloon injure group. After operation for 4 weeks ,the total cholesterol in doxazosin group was lower,and HDL-C was higher compared with balloon injure group. The intima thinkness were inhibited,neointima area were inhibited too, Lumen area was increased. Conclusion:Doxazosin can inhibit vascular stenosis formed by using high cholesterol diet plus balloon injured method,and reduce serum lipid and inhibite atherosclerotic progress.
出处 《中国误诊学杂志》 CAS 2005年第15期2808-2811,共4页 Chinese Journal of Misdiagnostics
关键词 多沙唑嗪/药理学 脂类/血液 血管内膜/药物作用 动脉硬化/药物疗法 Doxazosin/pharmacology Lipids/blood Tunicaintima/drug effects Arteriosclerosis/drug therapy
  • 相关文献

参考文献9

  • 1Tahmatzopoulos A,Rowland RG,Kyprianou N. The role of alphablockers in the management of prostate cancer[J]. Expert Opin Pharmacother, 2004,5(6): 1279-1285,.
  • 2吴运生,张红菱.实验性动脉再狭窄动物模型的构建与研究[J].南通医学院学报,2003,23(3):262-263. 被引量:9
  • 3Vashisht R,Sian M, franks PJ,et al. Long-term reduction of intimal hyperplasia by the selective alpha-1 adrenergic antagonist doxazosin[J]. Br J Surg,1992,79(11):1285-1288.
  • 4Wilson TA, Foxall TL, Nicolosi R J, et al. Doxazosin, an alpha-1 antagonist prevents further progression of the advanced atherosclerotic lesion in hypercholesterolemic hamsters[J]. Metabolism,2003,52(10):1240-1245.
  • 5杨君,赵仙先,秦永文,文军慧.多沙唑嗪抑制大鼠血管平滑肌细胞增殖的实验研究[J].中国动脉硬化杂志,2002,10(3):234-235. 被引量:6
  • 6Glanz M,Garber AJ,Mancia G,et al, Meta-analysis of studies using selective alpha1-blockers in patients with hypertension and type 2 diabetes[J]. Int J Clin Pract,2001,55(10):694-701.
  • 7卢竞前,曹晶茗.多沙唑嗪应用于心血管病的研究进展[J].现代中西医结合杂志,2005,14(9):1242-1244. 被引量:5
  • 8Wilson TA,Foxall TL,Nicolosi RJ, Doxazosin, an alpha-1 antagonis, prevents further progression of the advanced atherosclerotic lesion in hypercholesterolemic hamsters[J]. Metabolism,200S,52(10):1240-1245.
  • 9Kinoshita M,Shimazu N,Fujita M,et al. Doxazosin, an alpha1-adrenergic antihypertensive agent, decreases serum oxidized LDL[J]. Am J Hypertens, 2001,14(3): 267-270.

二级参考文献31

  • 1郗永安,汪丽蕙.血管成形术后再狭窄实验模型[J].中国介入心脏病学杂志,1995,3(4):189-191. 被引量:16
  • 2袁晋青.经皮冠状动脉腔内成形术后再狭窄的分子生物学机制[J].中国循环杂志,1996,11(9):570-573. 被引量:4
  • 3[7]Vashisht R, Sian M, Franks PJ, et al. Long-term reduction of intimal hyperplasia by the selective alpha-1 adrenergic antagonist doxazosin. Br J Surg, 1992, 79: 1 285-288
  • 4[1]Gibbons GH, Dzau VJ. Molecolar therapies for vascular disease. Science, 1996, 272: 689-693
  • 5[2]Hu ZW, Shi XY, Okazaki M, et al. Angiotensin Ⅱ induces transcription and expression of α1 -adrenergic receptors in vascular soomth muscle cells. Am J Physiol, 1995, 268: H1 006-014
  • 6[3]Hu ZW, Shi XY, Lin R, et al. α1-Adrenergic receptor subtypes: activation of phosphatidylinositol 3-kinase. Mol Biol Cell Suppl, 1995, 6: 128
  • 7[4]Ulrich K, Shu W, Sarah K, et al. Doxazosin inhibits retinoblastoma protein phosphorylation and G1-S transition in human coronary smooth muscle cells. Arterioscler Thromb Vasc Biol, 2000, 20: 1 216-224
  • 8[5]Kato JY, Matsuoka M, Polyak K, et al. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell, 1994, 79: 487-496
  • 9[6]Laufs U, Marra D, Node K, et al. 3 Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem, 1999, 274: 21 926-931
  • 10Oottsauner-- Wolf M, Moliterno DJ, Lincoff AM, et al.Restenosis -- An open file[J]. Clin Cardiol, 1996,19 :347.

共引文献17

同被引文献21

  • 1梁爱群.川芎嗪的药理及机理研究[J].时珍国医国药,2005,16(6):532-533. 被引量:86
  • 2史大卓,李静,马晓昌,张群豪,毛节明,陈明哲,陈可冀.血府逐瘀浓缩丸预防冠心病病人经皮冠状动脉腔内成形术后再狭窄的临床观察[J].中医杂志,1997,38(1):27-29. 被引量:61
  • 3LI Song, WANG Jian - Hua, CHEN Sheng - Lan. Inhibitory effect of tetramethylpyrazine on proliferation, of rabbit vascular smooth muscle cells after arterial injury[J]. Cta Pharmacologia Sinica , 1999, 20: 62 -63.
  • 4Landzberg BR, Frishman WH, Lerrick K. Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures[J]. Prog Cardiovasc Dis , 1997, 39 (4): 361-364.
  • 5Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after injury. In: smooth muscle growth in the absence of endothelium[J] . Lab Invest, 1983, 49(3) : 327 - 333.
  • 6Kester M. Therapeutic strategies for diabetes and complications: A role for sphingolipids. Adv Exp Med Biol, 2010,688..206-216.
  • 7Brenner BM, CooPer ME, Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type2 diabetes and nephropathy. N Engl J Med, 2001,345:861-869.
  • 8Lewis EJ,Hunsieker LG,ClarkeWR,et al. RenoProtective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001,345: 851-860.
  • 9Derynek R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature, 2003,425: 577- 584.
  • 10Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nat ure, 2001,414 : 813-820.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部